Board of Directors

Beth Seidenberg, MD

Partner, Kleiner Perkins Caufield & Byers

Dr. Beth Seidenberg focuses on life science investing in digital health and biotech and works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining Kleiner Perkins Caufield & Byers in 2005, Beth has incubated five companies and was the founding CEO of two. She serves on the board of directors of 5 Digital Health Companies: Auxogyn, Mango Health, RedBrick Health, Practice Fusion and Spruce Health and 9 Biotech Companies: 3-V Biosciences, ARMO Biosciences, ACIR Biosciences, Breathe Technologies, Flexus and True North, including 3 publicly traded companies: Atara Bio (ATRA), Epizyme (EPZM) and Tesaro (TSRO). Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.

Carl L. Gordon, PhD, CFA

Partner, OrbiMed

Carl is a founding Partner and Co-Head of Global Private Equity at OrbiMed. Mr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Mr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a bachelors degree from Harvard College.

Pierre Legault

Mr. Legault has over 25 years of executive leadership experience in the biopharmaceutical industry. Most recently, he served as Chief Executive Officer of NephroGenex from 2014 to 2016 and has served as Chairman of the Board since 2012. From 2010 to 2012, Mr. Legault was the Chief Executive officer of Prosidion. Previously, he was the Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 to 2010. In addition, Mr. Legault was the Senior Executive Vice President and Chief Administrative Officer of Rite Aid Corporation from 2006 to 2008 and President of Brooks Eckerd, which was acquired by Rite Aid. Earlier in his career, Mr. Legault worked for Sanofi-Aventis and predecessor companies over a 16 year period in several leadership positions, including President of Worldwide Dermatology Operations and Chief Financial Officer. Mr. Legault received a B.A.A. in Finance, Marketing and Accounting, as well as C.A., and C.P.A. certifications, from HEC Montreal. In addition, he earned an M.B.A. from McGill University and completed an executive master’s program at Harvard Business School.

Naiyer Rizvi, MD

Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Columbia University

Dr. Rizvi has over 20 years of experience in clinical and translational research. His research focus is in lung cancer and immunotherapeutic drug development. He is presently Professor of Medicine at Columbia University where he holds the Price Chair for Clinical Translational Medicine. He is Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy at Columbia. From 2002-2015, he worked at Memorial Sloan Kettering Cancer Center where he led lung cancer immunotherapy research and was an active member of the early immunotherapy drug development program. He earned his MD from University of Manitoba where he also did his Internal Medicine Residency. Dr. Rizvi obtained his Fellowship in Oncology from Beth Israel Hospital, Harvard Medical School.

Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer, ARMO BioSciences

Peter Van Vlasselaer, PhD has over 20 years of experience in the biotech industry and has founded and led several companies. In addition to founding ARMO, Peter was a founder of Arresto BioSciences and co-founder of TrueNorth and ACIR BioSciences. He currently serves on the boards of ARMO, TrueNorth, and Blade Therapeutics. Previously, Peter was President and CEO of iPierian, ARRESTO BioSciences and AVIDIA. Beforehand, he was member of the start-up teams of the publicly trading companies InterMune (ITMN) and Dendreon (DNDN), where he was Senior Vice President Technical Operations and Vice President of Drug Development, respectively. Peter was a post-doctoral fellow in the Division of Immunology and Rheumatology at Stanford University, CA and at the Laboratory of Human Immunology at DNAX Research Institute in Palo Alto, CA and obtained a bachelor's degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.